Adipotide vs AOD-9604
Emerging vs Well Studied
monitor Researched · 90% No published data on combined use or pharmacodynamic interaction.
Molecular Data
Adipotide AOD-9604
Weight N/A 1,815.1 Da
Half-life Not established 3-4 minutes
Chain N/A 17 amino acids
Type Chimeric peptidomimetic Modified hGH C-terminal fragment
Key Benefits
Adipotide
01 Rapid fat-mass reduction via selective white adipose tissue vascular targeting
02 Improved insulin sensitivity following adipose reduction
03 Non-CNS peripheral mechanism distinct from appetite suppressants
AOD-9604
01 Targets fat loss through selective lipolysis
02 Avoids growth hormone side effects
03 No effect on blood glucose or insulin
04 Does not increase IGF-1 levels
05 Metabolically safer than full hGH
06 Emerging cartilage repair potential
Dosing Protocols
Adipotide
0.43 mg/kg / Once daily
Primate Research Replication 0.43 mg/kg Once daily
Dose-Finding (Research) 0.10-0.75 mg/kg Once daily (escalating tiers)
AOD-9604
250-500mcg / Once daily
Fat loss - Standard 250-300mcg Once daily (morning, fasted)
Enhanced fat loss 400-500mcg Once daily (morning, fasted)
Joint support 250mcg Once daily
Conservative start 200mcg Once daily
Side Effects
Adipotide
Mild creatinine elevation
Electrolyte shifts
Dose-dependent proximal tubule changes (reversible in primates)
AOD-9604
Generally well-tolerated in clinical trials
Mild injection site reactions possible
No reported effects on blood glucose or insulin
Contraindications
Pregnancy/lactation (not studied)
Dehydration
Concurrent nephrotoxic medications
Pregnancy or breastfeeding
WADA prohibited - athletes subject to testing must avoid
Research Evidence
Adipotide AOD-9604
Status Emerging Well Studied
References 4 studies 5 studies
Latest — 2014
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.